14-day Premium Trial Subscription Try For FreeTry Free

Range Low Price High Price Comment
30 days $12.37 $15.43 Thursday, 2nd May 2024 URGN stock ended at $14.26. This is 0.97% less than the trading day before Wednesday, 1st May 2024. During the day the stock fluctuated 2.68% from a day low at $14.18 to a day high of $14.56.
90 days $12.37 $19.87
52 weeks $8.69 $24.13

Historical UroGen Pharma Ltd prices

Date Open High Low Close Volume
Feb 21, 2024 $19.10 $19.21 $17.54 $17.69 213 574
Feb 20, 2024 $19.18 $19.74 $19.01 $19.24 298 748
Feb 16, 2024 $18.59 $19.87 $18.15 $19.33 416 194
Feb 15, 2024 $19.22 $19.66 $18.68 $18.80 1 668 139
Feb 14, 2024 $19.01 $19.33 $18.87 $19.22 243 692
Feb 13, 2024 $18.78 $19.26 $18.44 $18.75 263 059
Feb 12, 2024 $18.98 $19.59 $18.97 $19.30 320 883
Feb 09, 2024 $18.53 $19.27 $18.53 $18.98 310 238
Feb 08, 2024 $16.32 $18.63 $16.14 $18.50 454 710
Feb 07, 2024 $15.95 $16.09 $15.63 $16.02 817 132
Feb 06, 2024 $15.90 $16.31 $15.84 $16.01 189 471
Feb 05, 2024 $16.30 $16.38 $15.83 $15.99 352 449
Feb 02, 2024 $15.75 $16.79 $15.75 $16.47 536 014
Feb 01, 2024 $15.76 $16.05 $15.45 $15.90 259 051
Jan 31, 2024 $15.84 $16.40 $15.67 $15.70 417 245
Jan 30, 2024 $15.97 $16.03 $15.48 $15.83 307 508
Jan 29, 2024 $16.20 $16.32 $15.76 $16.12 327 855
Jan 26, 2024 $15.49 $16.45 $15.12 $16.07 407 435
Jan 25, 2024 $15.26 $15.43 $14.52 $15.32 398 007
Jan 24, 2024 $15.75 $15.75 $14.85 $15.04 210 918
Jan 23, 2024 $15.22 $15.39 $14.75 $15.11 122 430
Jan 22, 2024 $14.87 $15.47 $14.60 $15.03 295 321
Jan 19, 2024 $14.32 $14.84 $13.44 $14.77 262 784
Jan 18, 2024 $15.67 $15.67 $14.15 $14.27 336 701
Jan 17, 2024 $14.67 $15.59 $14.33 $15.59 286 074
Click to get the best stock tips daily for free!

About UroGen Pharma Ltd

UroGen Pharma Ltd UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102, which is in Phase III clinical trials for the treatment of several forms... URGN Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT